

March 2018-August 2018

In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide. Please provide the number of patients by treatment for the following disease modifying drugs.

Drug Name	TOTAL
Aubagio (Teriflunomide)	26
Avonex (Interferon beta 1a)	8
Betaferon (interferon beta 1b)	2
Copaxone (Glatiramer acetate)	4
Extavia (beta interferon 1b)	0
Gilenya (Fingolimod)	18
Lemtrada (Alemtuzumab)	0
Rebif (beta interferon 1a)	7
Tecfidera (Dimethyl fumarate)	41
Tysabri (Natalizumab)	7
Ampyra (Fampyra)	13
Peginterferon beta 1a (Plegridy)	4
Daclizumab (Zinbryta)	0
Cladribine (Mavenclad)	0
Others	

2. For patients receiving Tysabri (natalizumab) what is the average waiting times to treatment, (i.e. once diagnosed and natalizumab selected as DMT of choice, how long do patients wait for their treatment to start) ?

There is no specific waiting list for this patient group.